US Patent

US8673893 — Substituted indazole derivatives active as kinase inhibitors

Method of Use · Assigned to Nerviano Medical Sciences SRL · Expires 2028-07-08 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent discloses substituted indazole derivatives and their use in pharmaceutical compositions for treating diseases associated with deregulated protein kinase activity.

USPTO Abstract

Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.

Drugs covered by this patent

Rozlytrek (entrectinib) · Roche

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2618`	—	Rozlytrek
`U-2618`	—	Rozlytrek

Patent Metadata

Patent number: US8673893
Jurisdiction: US
Classification: Method of Use
Expires: 2028-07-08
Drug substance claim: No
Drug product claim: No
Assignee: Nerviano Medical Sciences SRL
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.